美国芝加哥当地时间2025年5月30日至6月3日，一年一度的美国临床肿瘤学会（ASCO）年将盛大开启！作为肿瘤领域的年度盛会，其将一如既往地带来最前沿的肿瘤研究进展与诊疗理念，备受领域关注！当前，ASCO官网发布了2025 ASCO年会的摘要标题，【肿瘤资讯】特此整理结直肠癌和肛门癌领域的重磅研究，带大家先睹为快！
Plenary Session
全体大会
摘要号：LBA1
报告人： Frank A. Sinicrope丨Mayo Clinic Rocheste
英文标题：Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC).
中文标题：单纯标准化疗对比联合阿替利珠单抗辅助治疗III期DNA错配修复缺陷（dMMR）结肠癌的随机临床试验（Alliance A021502；ATOMIC研究）
Oral Abstract Session
口头报告
摘要号：LBA3500
报告人：Elena Elez丨Department of Medical Oncology, Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC
英文标题：First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses.
中文标题：一线康奈非尼+西妥昔单抗+mFOLFOX6方案治疗BRAF V600E突变转移性结直肠癌（BREAKWATER研究）：无进展生存期及更新总生存期分析
摘要号：3501
报告人：Heinz-Josef Lenz, MD丨University of Southern California Norris Comprehensive Cancer Center
英文标题：Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) or NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded analyses from CheckMate 8HW.
中文标题：纳武利尤单抗（NIVO）联合伊匹木单抗（IPI）对比化疗（chemo）或纳武利尤单抗单药治疗高度微卫星不稳定/错配修复缺陷（MSI-H/dMMR）转移性结直肠癌（mCRC）：CheckMate 8HW研究的扩展分析
摘要号： LBA3502
报告人：丁克峰丨浙江大学医学院附属第二医院
英文标题：Anlotinib versus bevacizumab added to standard first-line chemotherapy among patients with RAS/BRAF wild-type, unresectable metastatic colorectal cancer: A multicenter, prospective, randomised, phase 3 clinical trial (ANCHOR trial).
中文标题：安罗替尼对比贝伐珠单抗联合标准一线化疗治疗RAS/BRAF野生型不可切除转移性结直肠癌患者：一项多中心、前瞻性、随机、3期临床试验（ANCHOR研究）
摘要号：3503
报告人：Jeanne Tie丨Department of Medical Oncology, Peter MacCallum Cancer Centre and Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research
英文标题：ctDNA-guided adjuvant chemotherapy escalation in stage III colon cancer: Primary analysis of the ctDNA-positive cohort from the randomized AGITG dynamic-III trial (intergroup study of AGITG and CCTG).
中文标题：基于ctDNA指导的III期结肠癌辅助化疗升阶策略：随机AGITG DYNAMIC-III试验（AGITG与CCTG联合研究）ctDNA阳性队列的初步分析
摘要号：3504
报告人：Frank A. Sinicrope, MD丨Mayo Clinic Rochester
英文标题：Tissue-free circulating tumor DNA assay and patient outcome in a phase III trial of FOLFOX-based adjuvant chemotherapy (Alliance N0147).
中文标题：III期FOLFOX为基础辅助化疗临床试验中无创循环肿瘤DNA检测与患者预后的关系（Alliance N0147研究）
摘要号：3505
报告人：Ignace De Hingh, MD, PhD | Catharina Cancer Institute
英文标题：Perioperative systemic therapy for resectable colorectal peritoneal metastases: A multicenter randomized phase 3 trial (CAIRO6).
中文标题：可切除结直肠腹膜转移的围手术期系统治疗：一项多中心随机3期临床试验（CAIRO6研究）
摘要号：3506
报告人：John H. Strickler, MD丨Duke University Medical Center
英文标题：Long-term safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 (phase 1b).
中文标题：Sotorasib联合帕尼单抗和FOLFIRI方案治疗经治KRAS G12C突变转移性结直肠癌（mCRC）的长期安全性和疗效：CodeBreaK 101研究（1b期）
摘要号：3507
报告人： Antoine Hollebecque, MD丨Institut Gustave Roussy
英文标题：Efficacy and safety of olomorasib, a second-generation KRAS G12C inhibitor, plus cetuximab in KRAS G12C-mutant advanced colorectal cancer.
中文标题：二代KRAS G12C抑制剂olomorasib联合西妥昔单抗治疗KRAS G12C突变晚期结直肠癌的疗效与安全性
摘要号：3508
报告人：Iwona A. Lugowska丨Maria Sklodowska-Curie National Research Institute and Oncology Centre
英文标题：The KRAS G12C inhibitor MK-1084 for KRAS G12C–mutated advanced colorectal cancer (CRC): Results from KANDLELIT-001.
中文标题：KRAS G12C抑制剂MK-1084治疗KRAS G12C突变晚期结直肠癌（CRC）的疗效：KANDLELIT-001研究结果
Rapid Oral Abstract Session
快速口头报告
摘要号：3512
报告人：Veronica Conca丨Department of Translational Research and New
英文标题：Upfront modified FOLFOXIRI plus panitumumab (pan) versus FOLFOX/pan for unresectable RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: Overall survival (OS) results from the phase III TRIPLETE study by GONO.
中文标题：改良FOLFOXIRI联合帕尼单抗（pan）对比FOLFOX/pan一线治疗不可切除RAS/BRAF野生型（wt）转移性结直肠癌（mCRC）患者：III期TRIPLETE研究总生存期（OS）结果
摘要号： 3513
报告人： Lena Weiss丨Department of Medicine III, University Hospital Munich LMU
英文标题：FIRE-4 (AIO KRK-0114): Randomized study evaluating the efficacy of cetuximab re-challenge in patients with metastatic RAS wild-type colorectal cancer responding to first-line treatment with FOLFIRI plus cetuximab.
中文标题：FIRE-4研究（AIO KRK-0114）：评估西妥昔单抗再挑战治疗对一线FOLFIRI联合西妥昔单抗治疗有效的转移性RAS野生型结直肠癌患者疗效的随机研究
摘要号： 3514
报告人：Yoshinori Kagawa丨Department of Gastroenterological Surgery, Osaka International Cancer Institute
英文标题：Longitudinal ctDNA monitoring and prediction of anti-EGFR rechallenge outcomes in RAS/BRAF wild-type metastatic colorectal cancer (mCRC): The REMARRY & PURSUIT trials.
中文标题：RAS/BRAF野生型转移性结直肠癌（mCRC）抗EGFR再挑战疗效的纵向ctDNA监测与预测：REMARRY和PURSUIT试验
摘要号：LBA3515
报告人： Chiara Cremolini丨Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana and Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa
英文标题：Panitumumab retreatment followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA (ctDNA): Results of the phase II randomized PARERE trial by GONO.
中文标题：帕尼单抗再治疗序贯瑞戈非尼对比反向序贯方案治疗循环肿瘤DNA（ctDNA）RAS/BRAF野生型化疗难治性转移性结直肠癌患者：II期随机PARERE试验结果
摘要号： LBA3516
报告人：许剑民丨复旦大学附属中山医院
英文标题：JMT101 in combination with irinotecan and SG001 versus regorafenib in patients with metastatic colorectal adenocarcinoma (mCRC): Results of a randomized, controlled, open-label, phase II study.
中文标题：JMT101联合伊立替康及SG001对比瑞戈非尼治疗转移性结直肠腺癌（mCRC）患者的疗效：一项随机、对照、开放标签II期临床研究结果
摘要号：3517
报告人：Anwaar Saeed丨University of Pittsburgh Medical Center (UPMC) and UPMC Hillman Cancer Center
英文标题：Phase 2 dose expansion study of DSP107, a first-in-class bi-specific 4-1BB T-cell engager, with and without atezolizumab in metastatic MSS colorectal cancer patients.
中文标题：DSP107（first-in-class双特异性4-1BB T细胞衔接器）联合或不联合阿替利珠单抗治疗转移性MSS结直肠癌患者的II期剂量扩展研究
摘要号：3518
报告人：Aron Bercz丨Memorial Sloan Kettering Cancer Center
英文标题：Circulating tumor DNA as an early response indicator in anal squamous cell carcinoma treated with chemoradiation.
中文标题：循环肿瘤DNA作为肛管鳞状细胞癌放化疗早期疗效预测标志物的研究
摘要号：3519
报告人：靖昌庆丨山东第一医科大学附属省立医院
英文标题：Short-course radiotherapy followed by sintilimab and CAPOX as total neoadjuvant treatment in locally advanced rectal cancer: A prospective, randomized controlled trial (SPRING-01).
中文标题：短程放疗序贯信迪利单抗联合CAPOX方案作为局部进展期直肠癌全程新辅助治疗：一项前瞻性随机对照试验（SPRING-01研究）
摘要号：3520
报告人：Qian Shi丨Department of Quantitative Science Research, Mayo Clinic Rochester
英文标题：Proposed changes to the pathologic staging for colon cancer (CC): AJCC Colon Cancer Expert Panel (AJCCCCEP).
中文标题：结肠癌（CC）病理分期修订方案：美国癌症联合委员会结肠癌专家小组（AJCCCCEP）建议
Clinical Science Symposium
临床科学研讨会
摘要号： LBA3509
报告人：Sara K Cha丨Department of Medical Oncology, Dana-Farber Cancer Institute
英文标题：Association between empirical dietary inflammatory pattern (EDIP) and survival in patients with stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance).
中文标题：经验性饮食炎症模式（EDIP）与III期结肠癌患者生存期的相关性分析：CALGB/SWOG 80702
摘要号：LBA3510
报告人：Christopher M. Booth丨Queen's University
英文标题：A randomized phase III trial of the impact of a structured exercise program on disease-free survival (DFS) in stage 3 or high-risk stage 2 colon cancer: Canadian Cancer Trials Group (CCTG) CO.21 (CHALLENGE).
中文标题：结构化运动干预对III期或高危II期结肠癌患者无病生存期（DFS）影响的III期随机临床试验：加拿大癌症试验组（CCTG）CO.21（CHALLENGE）研究
摘要号：LBA3511
报告人：Sheraz Yaqub丨Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital and University of Oslo, Institute of Clinical Medicine
英文标题：Aspirin as secondary prevention for colorectal cancer liver metastases (ASAC): A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial.
中文标题：阿司匹林用于结直肠癌肝转移二级预防（ASAC研究）：一项多中心、随机、双盲、安慰剂对照III期临床试验
摘要号：104
报告人：林振宇丨华中科技大学同济医学院附属协和医院
英文标题：Efficacy and safety of IBI363 monotherapy or in combination with bevacizumab in patients with advanced colorectal cancer.
中文标题：IBI363单药或联合贝伐珠单抗治疗晚期结直肠癌患者的有效性和安全性分析
排版编辑：肿瘤资讯-QTT
苏公网安备32059002004080号
